FTC asks drugmakers for input ahead of likely reforms

The US Federal Trade Commission (FTC) – alongside colleagues at the Food and Drug Administration (FDA) – is trying to gain an insight into what impediments there are to fairness and competition in prescription drug markets.

With that and likely efforts from President Donald Trump to lower drug prices in mind, and ahead of a workshop with drugmakers and the bosses of both agencies next month, the FTC is inviting companies to give feedback on their experiences in these markets.

Part of the workshop will focus on the generic drug market, a sector that FDA Commissioner Scott Gottlieb has persistently  voiced his support for since taking on the role earlier this year.